Neurochemical Research

, Volume 40, Issue 5, pp 906–914 | Cite as

C3 Polymorphism Influences Circulating Levels of C3, ASP and Lipids in Schizophrenic Patients

  • Mohamed Jalloul Nsaiba
  • Marc Lapointe
  • Hajer Mabrouk
  • Wahiba Douki
  • Lotfi Gaha
  • Louis Pérusse
  • Claude Bouchard
  • Besma Bel Hadj Jrad
  • Katherine Cianflone
Original Paper


Excessive activation of complement is associated with many diseases including schizophrenia. Investigation of C3 polymorphisms, circulating C3, cleavage product ASP/C3adesArg, and lipid metabolism. Cross-sectional analysis. C3 genotyping (CC vs GG for R102L) was performed on 434 Tunisian people consisting of 272 schizophrenic (SZ) patients and 162 control subjects. In a age- and gender-matched subgroups of the three genotypes (131 SZ and 112 NOR), plasma triglycerides, total cholesterol (C), LDL-C, HDL-C, ASP, and complement C3 were measured. C3 gene polymorphism influences BMI and plasma C3, ASP, triglyceride, total cholesterol, LDL-C and HDL-C among SZ patients (p < 0.05–0.0001), with increasing values demonstrated from CC (common form) to CG (heterozygote form) to GG (rare homozygote) forms. Significant correlations between plasma C3 and BMI, triglyceride, HDL-C and ASP (p < 0.05–0.0001) were observed, while ASP correlated with BMI and LDL-C (p = 0.005, p = 0.001, respectively) in SZ patients. Further, proportional conversion of C3 to ASP (%ASP/C3) also increased (p < 0.0001, GG>CG>CC). C3 polymorphisms and plasma C3, ASP and %ASP/C3 correlated with lipid parameters in this SZ population, suggesting that factors predisposing patients to schizophrenia are permissive for complement pathway activation and dyslipidemic influences.


C3 polymorphism Lipid metabolism Schizophrenia Acylation stimulating protein/C3adesArg 



Body mass index


Complement 3


High-density and low-density lipoprotein-cholesterol









This study was supported by a Grant from CIHR (to KC). K. Cianflone holds a Canada Research Chair in Adipose Tissue. C Bouchard is partially funded by the John W. Barton Jr Chair in Genetics and Nutrition. MHN was supported by an exchange scholarship from the Ministry of Higher Education and Scientific Research in Tunisia. We appreciate the technical and manuscript assistance of Mélanie Cianflone.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Nauta AJ, Roos A, Daha MR (2004) A regulatory role for complement in innate immunity and autoimmunity. Int Arch Allergy Immunol 134:310–323CrossRefPubMedGoogle Scholar
  2. 2.
    Oksjoki R, Kovanen PT, Meri S, Pentikainen MO (2007) Function and regulation of the complement system in cardiovascular diseases. Front Biosci 12:4696–4708CrossRefPubMedGoogle Scholar
  3. 3.
    Haeffner-Cavaillon N (1998) Inflammatory response. Part 1. Rev Med Interne 19:585–588CrossRefPubMedGoogle Scholar
  4. 4.
    Takabayashi T, Vannier E, Burke JF, Tompkins RG, Gelfand JA, Clark BD (1998) Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J Infect Dis 177:1622–1628CrossRefPubMedGoogle Scholar
  5. 5.
    Onat A, Can G, Rezvani R, Cianflone K (2011) Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 412:1171–1179CrossRefPubMedGoogle Scholar
  6. 6.
    Cianflone K, Xia Z, Chen LY (2003) Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 1609:127–143CrossRefPubMedGoogle Scholar
  7. 7.
    Tichaczek-Goska D (2012) Deficiencies and excessive human complement system activation in disorders of multifarious etiology. Adv Clin Exp Med 21:105–114PubMedGoogle Scholar
  8. 8.
    Mayilyan KR, Weinberger DR, Sim RB (2008) The complement system in schizophrenia. Drug News Perspect 21:200–210CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Engström G, Hedblad B, Janzon L, Lindgärde F (2005) Weight gain in relation to plasma levels of complement factor 3: results from a population-based cohort study. Diabetologia 48:2525–2531CrossRefPubMedGoogle Scholar
  10. 10.
    van Oostrom AJ, Alipour A, Plokker TW, Sniderman AD, Cabezas MC (2007) The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis 190:167–173CrossRefPubMedGoogle Scholar
  11. 11.
    Hernández-Mijares A, Jarabo-Bueno MM, López-Ruiz A, Solá-Izquierdo E, Morillas-Ariño C, Martínez-Triguero ML (2007) Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes 31:927–932CrossRefGoogle Scholar
  12. 12.
    Phillips CM, Goumidi L, Bertrais S, Ferguson JF, Field MR, Kelly ED, Peloso GM, Cupples LA, Shen J, Ordovas JM, McManus R, Hercberg S, Portugal H, Lairon D, Planells R, Roche HM (2009) Complement component 3 polymorphisms interact with polyunsaturated fatty acids to modulate risk of metabolic syndrome. Am J Clin Nutr 90:1665–1673CrossRefPubMedGoogle Scholar
  13. 13.
    Ylitalo K, Pajukanta P, Meri S, Cantor RM, Mero-Matikainen N, Vakkilainen J, Nuotio I, Taskinen MR (2001) Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 21:838–843CrossRefPubMedGoogle Scholar
  14. 14.
    Alper CA, Propp RP (1968) Genetic polymorphism of the third component of human complement (C′3). J Clin Investig 47:2181–2191CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wieme RJ, Demeulenaere L (1967) Genetically determined electrophoretic variant of the human complement component C′3. Nature 214:1042–1043CrossRefPubMedGoogle Scholar
  16. 16.
    Leban N, Haj Khelil A, Daimi H, Denden S, Slimene F, Mehdouani K, Abdennaji Guenounou B, Lefranc G, Perrin P, Ben Chibani J (2007) C3 complement polymorphism in patients suffering from obstructive chronic bronchopneumopathy in Tunisia. Ann Biol Clin (Paris) 65:251–256Google Scholar
  17. 17.
    Zerbib J, Richard F, Puche N, Leveziel N, Cohen SY, Korobelnik JF, Sahel J, Munnich A, Kaplan J, Rozet JM, Souied EH (2010) R102G polymorphism of the C3 gene associated with exudative age-related macular degeneration in a French population. Mol Vis 16:1324–1330PubMedPubMedCentralGoogle Scholar
  18. 18.
    Császár A, Duba J, Melegh B, Kramer J, Szalai C, Prohászka Z, Karádi I, Kovács M, Méhes K, Romics L, Füst G (2001) Increased frequency of the C3*F allele and the Leiden mutation of coagulation factor V in patients with severe coronary heart disease who survived myocardial infarction. Exp Clin Immunogenet 18:206–212CrossRefPubMedGoogle Scholar
  19. 19.
    de Messias-Reason IJ, Aleixo V, de Freitas H, Nisihara RM, Mocelin V, Urbanetz A (2000) Complement activation in Brazilian patients with preeclampsia. J Investig Allergol Clin Immunol 10:209–214PubMedGoogle Scholar
  20. 20.
    Engström G, Hedblad B, Eriksson KF, Janzon L, Lindgärde F (2005) Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54:570–575CrossRefPubMedGoogle Scholar
  21. 21.
    Zakharyan R (2014) Inflammatory cytokine network in schizophrenia. World J Biol Psychiatry 15:174–187CrossRefPubMedGoogle Scholar
  22. 22.
    Saleh J, Summers LK, Cianflone K, Fielding BA, Sniderman AD, Frayn KN (1998) Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J Lipid Res 39:884–891PubMedGoogle Scholar
  23. 23.
    Smith JD, Cianflone K, Martin J, Poirier P, Broderick TL, Noël M (2011) Plasma adipokine and hormone changes in mountaineers on ascent to 5300 meters. Wilderness Environ Med 22:107–114CrossRefPubMedGoogle Scholar
  24. 24.
    Saleh J, Al-Wardy N, Farhan H, Al-Khanbashi M, Cianflone K (2011) Acylation stimulating protein: a female lipogenic factor? Obes Rev 12:440–448CrossRefPubMedGoogle Scholar
  25. 25.
    Del Giudice P, Blanc-Amrane V, Bes M, Lina G, Hubiche T, Counillon E, Vandenesch F, Etienne J (2009) A case of indigenous skin infection caused by methicillin-resistant Staphylococcus aureus USA300 in France. Ann Dermatol Venereol 136:541–542CrossRefPubMedGoogle Scholar
  26. 26.
    Boyajyan A, Zakharyan R, Khoyetsyan A (2012) Molecular and genetic indicators of aberrant immunity and apoptosis in schizophrenia, Chapter XI. In: Sumiyoshi T (ed) Schizophrenia research: recent advances. Section II: neuropsychobiological insights, series: mental illnesses and treatments. Nova Science Publishers Inc, USA, pp 183–240Google Scholar
  27. 27.
    Santos Sória Ld, Moura Gubert Cd, Ceresér KM, Gama CS, Kapczinski F (2012) Increased serum levels of C3 and C4 in patients with schizophrenia compared to eutymic patients with bipolar disorder and healthy. Rev Bras Psiquiatr 34:119–120CrossRefPubMedGoogle Scholar
  28. 28.
    Mayilyan KR, Arnold JN, Presanis JS, Soghoyan AF, Sim RB (2006) Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neurosci Lett 404:336–341CrossRefPubMedGoogle Scholar
  29. 29.
    Hakobyan S, Boyajyan A, Sim RB (2005) Classical pathway complement activity in schizophrenia. Neurosci Lett 374:35–37CrossRefPubMedGoogle Scholar
  30. 30.
    Boyajyan A, Khoyetsyan A, Chavushyan A (2010) Alternative complement pathway in schizophrenia. Neurochem Res 35:894–898CrossRefPubMedGoogle Scholar
  31. 31.
    Leonard BE, Schwarz M, Myint AM (2012) The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol 26:33–41CrossRefPubMedGoogle Scholar
  32. 32.
    Steiner J, Bernstein HG, Schiltz K, Müller UJ, Westphal S, Drexhage HA, Bogerts B (2014) Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma. Prog Neuropsychopharmacol Biol Psychiatry 48:287–294CrossRefPubMedGoogle Scholar
  33. 33.
    Welch TR, Beischel L, Kleesattel A (1990) Functional consequences of the genetic polymorphism of the third component of complement. J Pediatr 116:S92–S97CrossRefPubMedGoogle Scholar
  34. 34.
    Brönnestam R (1973) Studies on the C3 polymorphism. Relationship between phenotype and quantitative immunochemical measurements. Hum Hered 23:128–134CrossRefPubMedGoogle Scholar
  35. 35.
    Kay PH, Natsuume-Sakai S, Hayakawa J, Dawkins RL (1985) Different allotypes of C3 degrade at different rates. Immunogenetics 22:563–569CrossRefPubMedGoogle Scholar
  36. 36.
    Andrews PA, Finn JE, Mathieson PW, Sacks SH (1995) Molecular analysis of C3 allotypes related to transplant outcome in human renal allografts. Transplantation 60:1342–1346CrossRefPubMedGoogle Scholar
  37. 37.
    Stoffersen E, Jørgensen KA (1980) C3 polymorphism in patients with chronic uremia. Hum Hered 30:46–49CrossRefPubMedGoogle Scholar
  38. 38.
    Arvilommi H (1974) Capacity of complement c3 phenotypes to bind on to mononuclear cells in man. Nature 251:740–741CrossRefPubMedGoogle Scholar
  39. 39.
    Heurich M, Martínez-Barricarte R, Francis NJ, Roberts DL, Rodríguez de Córdoba S, Morgan BP, Harris CL (2011) Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA 108:8761–8766CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Fisette A, Poursharifi P, Oikonomopoulou K, Munkonda MN, Lapointe M, Cianflone K (2013) Paradoxical glucose-sensitizing yet proinflammatory effects of acute ASP administration in mice. Mediat Inflamm 713284Google Scholar
  41. 41.
    Paglialunga S, Fisette A, Munkonda M, Gao Y, Richard D, Cianflone K (2010) The effects of acylation stimulating protein supplementation VS antibody neutralization on energy expenditure in wildtype mice. BMC Physiol 10:4CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Vancampfort D, Wampers M, Mitchell AJ, Correll CU, De Herdt A, Probst M, De Hert M (2013) A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 12:240–250CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Limosin F, Gasquet I, Leguay D, Azorin JM, Rouillon F (2008) Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia. Acta Psychiatr Scand 118:19–25CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Mohamed Jalloul Nsaiba
    • 1
    • 2
  • Marc Lapointe
    • 1
  • Hajer Mabrouk
    • 3
  • Wahiba Douki
    • 3
  • Lotfi Gaha
    • 3
  • Louis Pérusse
    • 4
  • Claude Bouchard
    • 5
  • Besma Bel Hadj Jrad
    • 2
  • Katherine Cianflone
    • 1
  1. 1.Centre de Recherche de l’Institut Universitaire de Cardiologie & Pneumologie de QuébecUniversité LavalQuébecCanada
  2. 2.Laboratoire Génétique, Biodiversité et Valorisation des Bio-ressources (LR11ES41)Institut Supérieur de Biotechnologie de MonastirMonastirTunisie
  3. 3.Research Laboratory Vulnerability to Psychotic Disorders, LR05ES10, Psychiatry DepartmentUniversity Hospital of MonastirMonastirTunisie
  4. 4.Department of Kinesiology, Faculty of Medicine, Institute of Nutrition and Functional FoodsUniversité LavalQuébecCanada
  5. 5.Human Genomics LaboratoryPennington Biomedical Research CenterBaton RougeUSA

Personalised recommendations